Alzheimer disease biomarkers as outcome measures for clinical trials in MCI

Anna Caroli, Annapaola Prestia, Sara Wade, Kewei Chen, Napatkamon Ayutyanont, Susan M. Landau, Cindee M. Madison, Cathleen Haense, Karl Herholz, Eric M. Reiman, William J. Jagust, Giovanni B. Frisoni

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Background: The aim of this study was to compare the performance and power of the best-established diagnostic biological markers as outcome measures for clinical trials in patients with mild cognitive impairment (MCI). Methods: Magnetic resonance imaging, F-18 fluorodeoxyglucose positron emission tomography markers, and Alzheimer's Disease Assessment Scale-cognitive subscale were compared in terms of effect size and statistical power over different follow-up periods in 2 MCI groups, selected from Alzheimer's Disease Neuroimaging Initiative data set based on cerebrospinal fluid (abnormal cerebrospinal fluid Aβ1-42 concentration-ABETA+) or magnetic resonance imaging evidence of Alzheimer disease (positivity to hippocampal atrophy-HIPPO+). Biomarkers progression was modeled through mixed effect models. Scaled slope was chosen as measure of effect size. Biomarkers power was estimated using simulation algorithms. Results: Seventy-four ABETA+ and 51 HIPPO+ MCI patients were included in the study. Imaging biomarkers of neurodegeneration, especially MR measurements, showed highest performance. For all biomarkers and both MCI groups, power increased with increasing follow-up time, irrespective of biomarker assessment frequency. Conclusion: These findings provide information about biomarker enrichment and outcome measurements that could be employed to reduce MCI patient samples and treatment duration in future clinical trials.

Original languageEnglish
Pages (from-to)101-109
Number of pages9
JournalAlzheimer Disease and Associated Disorders
Volume29
Issue number2
DOIs
Publication statusPublished - Jun 9 2015

Fingerprint

Alzheimer Disease
Biomarkers
Outcome Assessment (Health Care)
Clinical Trials
Cerebrospinal Fluid
Magnetic Resonance Imaging
Fluorodeoxyglucose F18
Cognitive Dysfunction
Neuroimaging
Positron-Emission Tomography
Atrophy
Power (Psychology)

Keywords

  • Alzheimer disease
  • biomarkers
  • biomarkers power
  • clinical trials
  • enrichment biomarkers
  • mild cognitive impairment
  • outcome measures

ASJC Scopus subject areas

  • Geriatrics and Gerontology
  • Psychiatry and Mental health
  • Gerontology
  • Clinical Psychology

Cite this

Alzheimer disease biomarkers as outcome measures for clinical trials in MCI. / Caroli, Anna; Prestia, Annapaola; Wade, Sara; Chen, Kewei; Ayutyanont, Napatkamon; Landau, Susan M.; Madison, Cindee M.; Haense, Cathleen; Herholz, Karl; Reiman, Eric M.; Jagust, William J.; Frisoni, Giovanni B.

In: Alzheimer Disease and Associated Disorders, Vol. 29, No. 2, 09.06.2015, p. 101-109.

Research output: Contribution to journalArticle

Caroli, A, Prestia, A, Wade, S, Chen, K, Ayutyanont, N, Landau, SM, Madison, CM, Haense, C, Herholz, K, Reiman, EM, Jagust, WJ & Frisoni, GB 2015, 'Alzheimer disease biomarkers as outcome measures for clinical trials in MCI', Alzheimer Disease and Associated Disorders, vol. 29, no. 2, pp. 101-109. https://doi.org/10.1097/WAD.0000000000000071
Caroli, Anna ; Prestia, Annapaola ; Wade, Sara ; Chen, Kewei ; Ayutyanont, Napatkamon ; Landau, Susan M. ; Madison, Cindee M. ; Haense, Cathleen ; Herholz, Karl ; Reiman, Eric M. ; Jagust, William J. ; Frisoni, Giovanni B. / Alzheimer disease biomarkers as outcome measures for clinical trials in MCI. In: Alzheimer Disease and Associated Disorders. 2015 ; Vol. 29, No. 2. pp. 101-109.
@article{592b08c489844a2299d0e6cca14c20aa,
title = "Alzheimer disease biomarkers as outcome measures for clinical trials in MCI",
abstract = "Background: The aim of this study was to compare the performance and power of the best-established diagnostic biological markers as outcome measures for clinical trials in patients with mild cognitive impairment (MCI). Methods: Magnetic resonance imaging, F-18 fluorodeoxyglucose positron emission tomography markers, and Alzheimer's Disease Assessment Scale-cognitive subscale were compared in terms of effect size and statistical power over different follow-up periods in 2 MCI groups, selected from Alzheimer's Disease Neuroimaging Initiative data set based on cerebrospinal fluid (abnormal cerebrospinal fluid Aβ1-42 concentration-ABETA+) or magnetic resonance imaging evidence of Alzheimer disease (positivity to hippocampal atrophy-HIPPO+). Biomarkers progression was modeled through mixed effect models. Scaled slope was chosen as measure of effect size. Biomarkers power was estimated using simulation algorithms. Results: Seventy-four ABETA+ and 51 HIPPO+ MCI patients were included in the study. Imaging biomarkers of neurodegeneration, especially MR measurements, showed highest performance. For all biomarkers and both MCI groups, power increased with increasing follow-up time, irrespective of biomarker assessment frequency. Conclusion: These findings provide information about biomarker enrichment and outcome measurements that could be employed to reduce MCI patient samples and treatment duration in future clinical trials.",
keywords = "Alzheimer disease, biomarkers, biomarkers power, clinical trials, enrichment biomarkers, mild cognitive impairment, outcome measures",
author = "Anna Caroli and Annapaola Prestia and Sara Wade and Kewei Chen and Napatkamon Ayutyanont and Landau, {Susan M.} and Madison, {Cindee M.} and Cathleen Haense and Karl Herholz and Reiman, {Eric M.} and Jagust, {William J.} and Frisoni, {Giovanni B.}",
year = "2015",
month = "6",
day = "9",
doi = "10.1097/WAD.0000000000000071",
language = "English",
volume = "29",
pages = "101--109",
journal = "Alzheimer Disease and Associated Disorders",
issn = "0893-0341",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Alzheimer disease biomarkers as outcome measures for clinical trials in MCI

AU - Caroli, Anna

AU - Prestia, Annapaola

AU - Wade, Sara

AU - Chen, Kewei

AU - Ayutyanont, Napatkamon

AU - Landau, Susan M.

AU - Madison, Cindee M.

AU - Haense, Cathleen

AU - Herholz, Karl

AU - Reiman, Eric M.

AU - Jagust, William J.

AU - Frisoni, Giovanni B.

PY - 2015/6/9

Y1 - 2015/6/9

N2 - Background: The aim of this study was to compare the performance and power of the best-established diagnostic biological markers as outcome measures for clinical trials in patients with mild cognitive impairment (MCI). Methods: Magnetic resonance imaging, F-18 fluorodeoxyglucose positron emission tomography markers, and Alzheimer's Disease Assessment Scale-cognitive subscale were compared in terms of effect size and statistical power over different follow-up periods in 2 MCI groups, selected from Alzheimer's Disease Neuroimaging Initiative data set based on cerebrospinal fluid (abnormal cerebrospinal fluid Aβ1-42 concentration-ABETA+) or magnetic resonance imaging evidence of Alzheimer disease (positivity to hippocampal atrophy-HIPPO+). Biomarkers progression was modeled through mixed effect models. Scaled slope was chosen as measure of effect size. Biomarkers power was estimated using simulation algorithms. Results: Seventy-four ABETA+ and 51 HIPPO+ MCI patients were included in the study. Imaging biomarkers of neurodegeneration, especially MR measurements, showed highest performance. For all biomarkers and both MCI groups, power increased with increasing follow-up time, irrespective of biomarker assessment frequency. Conclusion: These findings provide information about biomarker enrichment and outcome measurements that could be employed to reduce MCI patient samples and treatment duration in future clinical trials.

AB - Background: The aim of this study was to compare the performance and power of the best-established diagnostic biological markers as outcome measures for clinical trials in patients with mild cognitive impairment (MCI). Methods: Magnetic resonance imaging, F-18 fluorodeoxyglucose positron emission tomography markers, and Alzheimer's Disease Assessment Scale-cognitive subscale were compared in terms of effect size and statistical power over different follow-up periods in 2 MCI groups, selected from Alzheimer's Disease Neuroimaging Initiative data set based on cerebrospinal fluid (abnormal cerebrospinal fluid Aβ1-42 concentration-ABETA+) or magnetic resonance imaging evidence of Alzheimer disease (positivity to hippocampal atrophy-HIPPO+). Biomarkers progression was modeled through mixed effect models. Scaled slope was chosen as measure of effect size. Biomarkers power was estimated using simulation algorithms. Results: Seventy-four ABETA+ and 51 HIPPO+ MCI patients were included in the study. Imaging biomarkers of neurodegeneration, especially MR measurements, showed highest performance. For all biomarkers and both MCI groups, power increased with increasing follow-up time, irrespective of biomarker assessment frequency. Conclusion: These findings provide information about biomarker enrichment and outcome measurements that could be employed to reduce MCI patient samples and treatment duration in future clinical trials.

KW - Alzheimer disease

KW - biomarkers

KW - biomarkers power

KW - clinical trials

KW - enrichment biomarkers

KW - mild cognitive impairment

KW - outcome measures

UR - http://www.scopus.com/inward/record.url?scp=84930753484&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930753484&partnerID=8YFLogxK

U2 - 10.1097/WAD.0000000000000071

DO - 10.1097/WAD.0000000000000071

M3 - Article

AN - SCOPUS:84930753484

VL - 29

SP - 101

EP - 109

JO - Alzheimer Disease and Associated Disorders

JF - Alzheimer Disease and Associated Disorders

SN - 0893-0341

IS - 2

ER -